Skip to content
Showing 21 - 30 of 141 results.
Researchers at Columbia and Harvard compared how the immune systems of volunteers responded to the new bivalent boosters versus the original vaccine.
Results show the new shots perform similarly to past ones. Moderna, Pfizer boosters aim to protect against new variants
Controversy surrounding a study that involved modifying the SARS-CoV-2 virus has prompted researchers to call for better guidance from funders.
Is five days of treatment of Paxlovid enough?
Regeneron will supply an additional 1.4 million antibody doses to the United States, while Eli Lilly will provide 388,000 additional doses of its antibodies.
BA.4.6 is now causing an estimated 7% to 10% of new Covid-19 infections, according to data from the US Centers for Disease Control and Prevention.
Paxlovid’s rebounds happened in 1-2% of patients. Should people take Paxlovid for longer periods of time to avoid rebound infections?
Dr. David Ho's interview with David Zierler, Director of the Caltech Heritage Project.
The latest dominant COVID-19 strain in the United States appears to be far better at evading antibodies than its predecessors, scientists say.
Lab studies identify resistance mutations in SARS-CoV-2’s protease, and some circulating variants have them
